Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.025
0 %
$ 43.9 K
Market Cap
0.0
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart CLVR
FINANCIALS
Balance Sheet
Clever Leaves Holdings Inc.
| Current Assets | 13.9 M |
| Cash & Short-Term Investments | 6.83 M |
| Receivables | 2.08 M |
| Other Current Assets | 5.03 M |
| Non-Current Assets | 17.3 M |
| Long-Term Investments | 0 |
| PP&E | 13.2 M |
| Other Non-Current Assets | 4.15 M |
| Current Liabilities | 5.81 M |
| Accounts Payable | 2.06 M |
| Short-Term Debt | 884 K |
| Other Current Liabilities | 2.86 M |
| Non-Current Liabilities | 1.22 M |
| Long-Term Debt | 1.2 M |
| Other Non-Current Liabilities | 12 K |
EFFICIENCY
Earnings Waterfall
Clever Leaves Holdings Inc.
| Revenue | 17.4 M |
| Cost Of Revenue | 10.9 M |
| Gross Profit | 6.56 M |
| Operating Expenses | 21.2 M |
| Operating Income | -15.6 M |
| Other Expenses | 4.2 M |
| Net Income | -19.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clever Leaves Holdings Inc.
| Net Income | -19.8 M |
| Depreciation & Amortization | 2.85 M |
| Capital Expenditures | -31 K |
| Stock-Based Compensation | 818 K |
| Change in Working Capital | 135 K |
| Others | 3.56 M |
| Free Cash Flow | -11.5 M |
Wall Street Analysts Price Targets
Clever Leaves Holdings Inc.
CLVR has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
CLVR does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Clever Leaves Holdings Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
2.19 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
10 months ago
Mar 08, 2024
|
Sell 563
USD
|
Hague Henry R III
Chief Financial Officer
|
- 170
|
3.3108 USD |
|
11 months ago
Feb 27, 2024
|
Sell 1.62 K
USD
|
Hague Henry R III
Chief Financial Officer
|
- 411
|
3.95 USD |
|
1 year ago
Jan 19, 2024
|
Sell 378
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 131
|
2.884 USD |
|
1 year ago
Jan 19, 2024
|
Sell 4.5 K
USD
|
Fajardo Andres
Chief Executive Officer
|
- 1561
|
2.884 USD |
|
1 year ago
Dec 20, 2023
|
Sell 360
USD
|
Fajardo Andres
Chief Executive Officer
|
- 177
|
2.0367 USD |
|
1 year ago
Dec 20, 2023
|
Sell 275
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 135
|
2.0367 USD |
|
1 year ago
Dec 20, 2023
|
Sell 275
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 135
|
2.0367 USD |
|
1 year ago
Dec 20, 2023
|
Sell 360
USD
|
Fajardo Andres
Chief Executive Officer
|
- 177
|
2.0367 USD |
|
1 year ago
Jul 18, 2023
|
Sell 175
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 813
|
0.2152 USD |
|
1 year ago
Jul 18, 2023
|
Sell 336
USD
|
Hague Henry R III
Chief Financial Officer
|
- 1560
|
0.2152 USD |
|
1 year ago
Jul 18, 2023
|
Sell 632
USD
|
Fajardo Andres
Chief Executive Officer
|
- 2938
|
0.2152 USD |
|
1 year ago
Jun 29, 2023
|
Sell 51.7
USD
|
Muecke William
Director
|
- 251
|
0.2058 USD |
|
1 year ago
Jun 29, 2023
|
Sell 51.7
USD
|
Julien Gary M
Director
|
- 251
|
0.2058 USD |
|
1 year ago
Mar 03, 2023
|
Sell 2.09 K
USD
|
Hague Henry R III
Chief Financial Officer
|
- 5678
|
0.3682 USD |
|
1 year ago
Feb 24, 2023
|
Sell 3.83 K
USD
|
Hague Henry R III
Chief Financial Officer
|
- 9018
|
0.4249 USD |
|
1 year ago
Feb 22, 2023
|
Sell 4.28 K
USD
|
Hague Henry R III
Chief Financial Officer
|
- 9728
|
0.4402 USD |
|
2 years ago
Jan 17, 2023
|
Sell 23.1 K
USD
|
Fajardo Andres
Chief Executive Officer
|
- 57669
|
0.4006 USD |
|
2 years ago
Jan 17, 2023
|
Sell 1.83 K
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 4557
|
0.4006 USD |
|
2 years ago
Dec 20, 2022
|
Sell 1.75 K
USD
|
Fajardo Andres
Chief Executive Officer
|
- 5133
|
0.34 USD |
|
2 years ago
Dec 20, 2022
|
Sell 1.3 K
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 3829
|
0.34 USD |
|
2 years ago
Jul 06, 2022
|
Sell 297
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 288
|
1.03 USD |
|
2 years ago
Jul 06, 2022
|
Sell 582
USD
|
Kastin David
General Counsel
|
- 565
|
1.03 USD |
|
2 years ago
Jul 06, 2022
|
Sell 616
USD
|
Hague Henry R III
Chief Financial Officer
|
- 598
|
1.03 USD |
|
2 years ago
Jul 06, 2022
|
Sell 1.21 K
USD
|
Fajardo Andres
Chief Executive Officer
|
- 1170
|
1.03 USD |
|
2 years ago
Mar 03, 2022
|
Sell 2.36 K
USD
|
Kastin David
General Counsel
|
- 2364
|
1 USD |
|
2 years ago
Mar 03, 2022
|
Sell 4.98 K
USD
|
Hague Henry R III
Chief Financial Officer
|
- 4981
|
1 USD |
|
3 years ago
Dec 30, 2021
|
Sell 0
USD
|
Detwiler Kyle
Chief Executive Officer
|
- 46390
|
0 USD |
|
3 years ago
Dec 30, 2021
|
Sell 148 K
USD
|
Detwiler Kyle
Chief Executive Officer
|
- 46390
|
3.1989 USD |
|
3 years ago
Dec 30, 2021
|
Sell 5.36 K
USD
|
Kastin David
General Counsel
|
- 1677
|
3.1989 USD |
|
3 years ago
Dec 30, 2021
|
Sell 14.3 K
USD
|
Fajardo Andres
President
|
- 4472
|
3.1989 USD |
|
3 years ago
Dec 30, 2021
|
Sell 10.6 K
USD
|
Wilches Julian
Chief Regulatory Officer
|
- 3316
|
3.1989 USD |
7. News
Clever Leaves Announces Voluntary Delisting and SEC Deregistration
TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, today announced that its Board of Directors (the “Board”) determined to voluntarily delist its common shares, without par value (the “common shares”) and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the “Warrants” and together with the common shares, the “Securities”) from The Nasdaq Stock Market LLC (“Nasdaq”) and deregister its Securities in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”).
globenewswire.com
- 9 months ago
Clever Leaves Reports Fourth Quarter and Full Year 2023 Results
- 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023. All financial information is provided in US dollars unless otherwise indicated.
globenewswire.com
- 10 months ago
High Growth: Top Pot Stocks Making Moves into March 2024
As the cannabis industry continues to flourish in the United States, investors are keenly watching the market for top-performing marijuana stocks. With the industry projected to reach a staggering $30 billion by 2025, the allure of double-digit gains before March is strong. Recent updates on federal legalization efforts have further invigorated the market. These developments promise to expand the industry's legal framework, potentially unlocking vast untapped markets. Investors are advised to employ technical analysis and proper risk management strategies. These tools are crucial for navigating the volatile cannabis sector. They help identify promising entry and exit points, maximizing returns while minimizing risks.
marijuanastocks.com
- 10 months ago
Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia
TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds (“Paradise”), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for cultivation across Colombia and Latin America. The two companies have already begun rigorous selection, phenotyping, and agronomic trials of several Paradise varieties at Clever Leaves' facility in order to register market-leading cultivars for production and commercialization.
globenewswire.com
- 11 months ago
Clever Leaves Granted Australian GMP Certification for Cannabis Products by the Therapeutic Goods Administration (TGA)
Multinational operator has been granted Australian GMP certification by the TGA for the manufacturing of cannabis products.
globenewswire.com
- 1 year ago
Clever Leaves Holdings Inc. Investor Reminder: Robbins LLP is Investigating Clever Leaves Holdings Inc. on Behalf of Investors
SAN DIEGO--(BUSINESS WIRE)---- $CLVR #CleverLeavesHoldingsInc--Clever Leaves Holdings Inc. Investor Reminder: Robbins LLP is Investigating Clever Leaves Holdings Inc. on Behalf of Investors.
businesswire.com
- 1 year ago
Robbins LLP Reminds Investors it is Investigating Clever Leaves Holdings Inc. on Behalf of Shareholder
SAN DIEGO--(BUSINESS WIRE)---- $CLVR #CleverLeavesHoldingsInc--Robbins LLP Reminds Investors it is Investigating Clever Leaves Holdings Inc. on Behalf of Shareholder.
businesswire.com
- 1 year ago
Calling All Clever Leaves Holdings Inc. (CLVR) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK--(BUSINESS WIRE)---- $CLVR #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA, SAMAW, and SAMAU) (“Schultze”), which merged with Clever Leaves Holdings Inc. (“Clever Leaves”) (NASDAQ: CLVR) on December 17, 2020. Investors who purchased Schultze are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/clvr. Inv.
businesswire.com
- 1 year ago
Calling All Clever Leaves Holdings Inc. (CLVR) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK--(BUSINESS WIRE)---- $CLVR #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA, SAMAW, and SAMAU) (“Schultze”), which merged with Clever Leaves Holdings Inc. (“Clever Leaves”) (NASDAQ: CLVR) on December 17, 2020. Investors who purchased Schultze are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/clvr. In.
businesswire.com
- 1 year ago
Clever Leaves Holdings, Inc. (CLVR) Q3 2023 Earnings Call Transcript
Clever Leaves Holdings, Inc. (NASDAQ:CLVR ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Jackie Keshner - Director of Investor Relations Andres Fajardo - Chief Executive Officer Hank Hague - Chief Financial Officer Conference Call Participants Bobby Burleson - Canaccord Genuity Operator Good day, and welcome Clever Leaves Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode.
seekingalpha.com
- 1 year ago
Clever Leaves Reports Third Quarter 2023 Results
- Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue -
globenewswire.com
- 1 year ago
Clever Leaves to Hold Third Quarter 2023 Conference Call on Thursday, November 9, 2023 at 5:00 p.m. ET
TOCANCIPÁ, Colombia, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, will hold a conference call on Thursday, November 9, 2023 at 5:00 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2023. The Company will provide its financial results in a press release prior to the conference call.
globenewswire.com
- 1 year ago
8. Profile
Summary
Clever Leaves Holdings Inc. CLVR
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 43.9 K
Dividend Yield
0.00%
Description
Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.
Contact
6501 Congress Avenue, Boca Raton, FL, 33487
https://www.cleverleaves.com
IPO
Date
Dec. 18, 2020
Employees
296
Officers
Ms. Marta Pinto Leite
General Counsel & Corporate Secretary
Mr. Henry R. Hague III
Chief Financial Officer
Mr. Julian Wilches
Chief Regulatory Officer
Mr. Andres Fajardo
Co-Founder, Chief Executive Officer & Director
Ms. Caroline Kliess
Managing Director of Germany
Mr. Andrew Miller
Head of Business Development
Ms. Jackie Keshner
Investor Relations Executive
Mr. Gustavo Escobar
Chief Operating Officer
Mr. Camilo Bohorquez
Head of Colombia